KRAS and neoplasm: In SW1116 and HCT116 human colon cancer cells with KRAS mutations, treatment with Ab3‐8 reduced intracellular glutamine transport, phosphorylation of AKT and ERK, and inhibited in vivo tumor growth of these cells in athymic mice.